Beyond PD-L1 IHC (TMB, Immune Microenvironment)

被引：0
|
作者：
Mino-Kenudsen, M. [1 ]
机构：
[1] Massachusetts Gen Hosp, Pathol, Boston, MA 02114 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Tumor Mutation Burden; immune microenvironment; immune checkpoint inhibitor; BLOCKADE;
D O I：
10.1016/j.jtho.2019.08.216
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBS08.02
引用
收藏
页码：S97 / S98
页数：2
相关论文
共 50 条
  • [21] Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
    Jiang, Xianjie
    Wang, Jie
    Deng, Xiangying
    Xiong, Fang
    Ge, Junshang
    Xiang, Bo
    Wu, Xu
    Ma, Jian
    Zhou, Ming
    Li, Xiaoling
    Li, Yong
    Li, Guiyuan
    Xiong, Wei
    Guo, Can
    Zeng, Zhaoyang
    MOLECULAR CANCER, 2019, 18 (1)
  • [22] PD-L1 expression and tumour microenvironment immune type groups in meningioma
    Turner, C.
    Mclay, J.
    Correia, J.
    Highet, B.
    Curtis, M.
    Hermans, I.
    Dragunow, M.
    HISTOPATHOLOGY, 2022, 81 : 142 - 142
  • [23] Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
    Pratistha Koirala
    Michael E. Roth
    Jonathan Gill
    Sajida Piperdi
    Jordan M. Chinai
    David S. Geller
    Bang H. Hoang
    Amy Park
    Michael A. Fremed
    Xingxing Zang
    Richard Gorlick
    Scientific Reports, 6
  • [24] Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
    Koirala, Pratistha
    Roth, Michael E.
    Gill, Jonathan
    Piperdi, Sajida
    Chinai, Jordan M.
    Geller, David S.
    Hoang, Bang H.
    Park, Amy
    Fremed, Michael A.
    Zang, Xingxing
    Gorlick, Richard
    SCIENTIFIC REPORTS, 2016, 6
  • [25] Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
    Koirala, Pratistha
    Roth, Michael
    Gill, Jonathan
    Chinai, Jordan
    Piperdi, Sajida
    Geller, David
    Hoang, Bang
    Poon, Vincent
    Zang, Xingxing
    Gorlick, Richard
    CANCER RESEARCH, 2016, 76
  • [26] HIGHER IMMUNE ASSOCIATED MARKERS (PD-L1, PD-1, TMB, MSI) IN GLIOSARCOMA COMPARED TO GLIOBLASTOMA.
    Phuphanich, S.
    Sanai, N.
    Xiu, J.
    Mittal, S.
    Michelhaugh, S.
    Subramaniam, D. S.
    Pandey, M. K.
    Kesari, S.
    Heimberger, A. B.
    Gatalica, Z.
    Korn, W. M.
    Sumrall, A. L.
    NEURO-ONCOLOGY, 2018, 20 : 242 - 243
  • [27] Interlaboratory-concordance of PD-L1 IHC for NSCLC
    Scheel, Andreas H.
    Banfer, Gudrun
    Baretton, Gustavo Bruno
    Dietel, Manfred
    Diezko, Rolf
    Henkel, Thomas
    Heukamp, Lukas C.
    Jasani, Bharat
    Johrens, Korinna
    Kirchner, Thomas
    Petersen, Iver
    Reu, Simone
    Schildhaus, Hans-Ulrich
    Schirmacher, Peter
    Tiemann, Markus
    Warth, Arne
    Weichert, Wilko
    Wolf, Juergen
    Ruschoff, Josef
    Buettner, Reinhard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] PD-L1 IHC in NSCLC with a global and methodological perspective
    Thunnissen, Erik
    de langen, Adrianus J.
    Smit, Egbert F.
    LUNG CANCER, 2017, 113 : 102 - 105
  • [29] Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
    Aden, Durre
    Zaheer, Samreen
    Sureka, Niti
    Trisal, Monal
    Chaurasia, Jai Kumar
    Zaheer, Sufian
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 269
  • [30] Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
    Tabana, Yasser
    Okoye, Isobel S.
    Siraki, Arno
    Elahi, Shokrollah
    Barakat, Khaled H.
    FRONTIERS IN ONCOLOGY, 2021, 11
12345